Send to

Choose Destination
Zhong Xi Yi Jie He Xue Bao. 2003 Sep;1(3):184-6.

[Clinical observation of cinobufacini injection used to treat moderate and advanced primary liver cancer].

[Article in Chinese]

Author information

Department of Traditional Chinese Medicine, Changhai Hospital, Second Military Medical University, Shanghai 200433, China.



To observe the clinical effect of cinobufacini injection in treating moderate and advanced primary liver cancer (PLC).


One hundred patients with moderate and advanced PLC were randomly divided into cino-treated group (50 patients) and control group (50 patients). The quality of life, tumor size, some changes of laboratory tests, and survival time were observed.


The progressive rate of cino-treated group (18%) was lower than that of the control group (32%). The quality of life of the cino-treated group (80%) was better than that of the control group (72%), but without statistical significance. The survival rate of >12 months of the cino-treated group (30%) was higher than that of the control group (18%). The patients' liver function such as serum total bilirubin and ALT decreased obviously in the cino-treated group while increased a lot in the control group. The level of AFP increased after treatment with statistical significance in the control group while there was no statistical significance in the cino-treated group.


Cinobufacini injection can not only inhibit the proliferation of cancer, but also protect liver function, improve quality of life and prolong survival time.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center